Genmab at record high after cancer drug trial data
28/10/2026 14:00
BUZZ-Genmab at record high after cancer drug trial data ** Shares in Genmab GMAB.CO jump around 17% to their highest ever after the Danish biotech company said its petosemtamab met both primary endpoints in a Phase 3 head and neck cancer trial
** The company shares crown the pan-European 600 index .STOXX at 1350 GMT
** Phase3 trial showed Genmab's petosemtamab combination helped head and neck cancer patients live longer and respond better to treatment
** If gains hold, shares will see their best day since 2018
(Reporting by Jesus Calero)
Recent news on Genmab A/S
See all newsGenmab falls after small cancer drug sales miss, lack of outlook hike
Genmab A/S reports results for the quarter ended September 30 - Earnings Summary
Danish biotech firm Genmab's nine-month revenue up on higher royalties and product sales
Europe Research Roundup: Airbus, Corbion, L'Oreal
Genmab at record high after cancer drug trial data